drugset
drugset / Trial / NCT04679870

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

NCT04679870 ↗

Phase 2 Active not recruiting 21 enrolled Galecto Biotech AB OPIS s.r.l · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is an open label, phase IIa trial in subjects with Myelofibrosis

Timeline

Start
2021-06-09
Primary completion
2023-12-31
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GB2064 Small molecule 1000 mg Oral

Indications

myelofibrosis